Pharmacologic therapy for coronary atherosclerosis in patients with Type 2 diabetes mellitus.
Accelerated progression of coronary atherosclerosis underlies the heightened cardiovascular risk observed in diabetic patients. As the worldwide prevalence of diabetes escalates in association with the incidence of abdominal obesity, the global burden of cardiovascular disease will continue to rise. Therapeutic strategies that have had the greatest cardiovascular benefit in diabetes have focused on lowering LDL-cholesterol and blood pressure, rather than glucose-lowering specifically. More recently, arterial wall imaging has helped characterize the natural history of coronary atherosclerosis in diabetes, the impact of associated risk factors and the influence of medical therapies.
Galla
John M
JM
Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA. nd.grad.88@gmail.com
Nicholls
Stephen J
SJ
D050153:Abdominal Fat / Q000503:physiopathology; D050197:Atherosclerosis / Q000188:drug therapy* / Q000209:etiology; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D018450:Disease Progression; D006801:Humans; D009765:Obesity / Q000503:physiopathology; D012307:Risk Factors
D008078:Cholesterol, LDL